Nautilus BiotechnolgyNAUT
About: Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Employees: 155
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
400% more call options, than puts
Call options by funds: $25K | Put options by funds: $5K
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
1.19% less ownership
Funds ownership: 50.86% [Q4 2024] → 49.67% (-1.19%) [Q1 2025]
2% less funds holding
Funds holding: 86 [Q4 2024] → 84 (-2) [Q1 2025]
43% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 30
50% less capital invested
Capital invested by funds: $107M [Q4 2024] → $54M (-$53.3M) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for NAUT.
Financial journalist opinion









